2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Kidney Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
Docetaxel
409
pembrolizumab
331
Prednisone
290
enzalutamide
285
Gemcitabine
274
Radiotherapy
270
Magnetic Resonance Spectroscopy
269
Nivolumab
253
Abiraterone Acetate
218
Cisplatin
212
Leuprolide
195
Radiosurgery
192
Sunitinib
188
Carboplatin
161
Androgen Antagonists
156
bicalutamide
152
Specimen Handling
149
Goserelin
149
Ipilimumab
131
Paclitaxel
126
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
122
apalutamide
118
Cyclophosphamide
117
Bevacizumab
116
Sorafenib
114
Everolimus
111
abiraterone
108
cabozantinib
105
atezolizumab
105
Biopsy
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Molecular Imaging
×
Genitourinary
×
Clear all
NCT02813226
2021-12-21
MISTER
Ontario Clinical Oncology Group (OCOG)
Phase NA
Completed
36 enrolled
NCT02228954
2021-12-07
IMPACT-RCC
Radboud University Medical Center
Completed
40 enrolled